glp 1 press conference Trump Announces Reduced GLP-1 Costs! Fmr. FDA Commissioner weighs in

Diabetes Care 35 , 14461454 (2012)

In 2024, the FDA approved Zepbound as the first GLP-1 medication specifically indicated to treat obstructive sleep apnea (OSA) in adults with obesity

When people think about the scale of the pharmaceutical industry, revenue and blockbuster drugs usually dominate the conversation

Most weight loss peptides act by: Increasing satiety signalling Delaying gastric emptying Modulating insulin and glucagon pathways Influencing energy expenditure However, research consistently shows that outcomes are influenced by diet composition, caloric intake, sleep quality, and physical activity

The discovery that GLP-2 promotes mucosal growth in the intestine is described, and key findings from both preclinical studies and the GLP-2 clinical development program for short bowel syndrome (SBS) are reviewed

Abstract Estimates suggest that there are currently 122.8 million adults 6599 years of age living with diabetes, of whom 9095% are diagnosed with type 2 diabetes (T2D)